Aqix Limited Logo AQIX® Fluid Technology.
Designed-Developed-Patented-Manufactured.
The World's Only Synthetic Human Interstitial Fluid


Latest news:

JUNE 2011

Aqix Limited is awarded a Research and Development Grant from the Technology Strategy Board for intravenous application of AQIX® RS-I.

AUGUST 2011

Aqix Limited patent for the intravenous application of AQIX® RS-I is granted in South Africa.

APRIL 2012

Aqix Limited is to participate as an SME member of the Consortium on Organ Preservation in Europe (COPE) grant award for €5.9M during 2013-17 to provide AQIX® RS-I as the base solution in the quest for improved, normothermic graft preservation of human donor organs.

DECEMBER 2012

Aqix Limited receives a notification of intent from the European Patent Office to be granted a EU patent filed in July, 2008, for applications of AQIX® RS-I involving blood/body fluid volume replacement therapies.

 

FEBRUARY 2013

European Patent Office grants Aqix Ltd a EU patent for intravenous applications of AQIX® RS-I involving blood/body fluid volume replacement therapies.



About Aqix


Aqix Ltd is a healthcare company that has identified valuable niche opportunities in clinical development for it's lead technology AQIX® RS-I, in the specific areas of infusion therapy, organ transplant perfusion and cell or tissue biospecimen collection and preservation.

In the management of hypovolaemia, AQIX® RS-I, is the first in a new generation of therapeutic products that focuses on maintaining homeostasis using the essential factors and mechanisms found in human serum and interstitial fluid-gels, at their normal physiological concentrations.

It is an exquisite and simple concept that is very easy to market to clinicians. The company has patents covering the formulation, manufacturing process and use of its innovation.

Aqix Ltd is committed to improving patients’ quality of life wherever needed: whether in hospitals, medical centres or at the point of diagnosis through personalised medicine.